Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Respiratory combination vaccine (Yantai Patronus Biotech)
- Development stage
- Preclinical
- Lead developer
- Yantai Patronus Biotech
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The Respiratory Combination Vaccine is a recombinant protein vaccine candidate developed by Yantai Patronus Biotech using its proprietary Universal Virus-like Particle (U-VLP®) technology platform. This vaccine is designed to provide protection against multiple respiratory pathogens simultaneously, addressing respiratory combination infections. The U-VLP® platform is engineered to present antigens in a way that mimics the structure of native viruses to elicit a robust immune response. As of early 2024, the candidate is in the preclinical and IND-enabling stage, with the company actively pursuing regulatory filings for clinical trials both domestically in China and internationally.
- Other names
- 呼吸道联苗Respiratory combination vaccine
Beyond the preview
Go deeper on Respiratory combination vaccine (Yantai Patronus Biotech).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Respiratory combination vaccine (Yantai Patronus Biotech).